Loading...
RAS And MAPK Cancer Pipeline Will Drive Long Term Upside Potential
AN
AnalystConsensusTarget
Not Invested
Based on Analyst Price Targets
Published
22 Jan 26
Views
66
22 Jan
US$3.78
AnalystConsensusTarget's Fair Value
US$16.13
76.6% undervalued intrinsic discount1Y
-8.9%7D
-8.3%1Y
-8.9%7D
-8.3%Author's Valuation
US$16.1376.6% undervalued intrinsic discount
AnalystConsensusTarget Fair Value